Investor Presentaiton

Top-tier talent Differentiated process Scalable platform 2021 investment funnel highlights disciplined approach 2021 Royalty Pharma investment activity >300 initial reviews ~85 CDAs signed 61 in-depth reviews 33 proposals submitted Executed 5 transactions for $3.0bn (1) (Acquired royalties on 10 therapies) Maintained strong financial discipline: ~3-4% of initial reviews resulted in an acquired royalty ROYALTY PHARMA CDA: confidential disclosure agreement 1. Data reflects total announced transaction value in 2021 ($2.3bn of total is upfront). 61

View entire presentation